# Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

> **NCT02578680** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 616 (actual)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab 200 mg
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DIETARY_SUPPLEMENT:** Folic acid 350-1000 μg
- **DIETARY_SUPPLEMENT:** Vitamin B12 1000 μg
- **DRUG:** Dexamethasone 4 mg
- **DRUG:** Saline solution

## Key facts

- **NCT ID:** NCT02578680
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-15
- **Primary completion:** 2017-11-08
- **Final completion:** 2023-06-22
- **Target enrollment:** 616 (ACTUAL)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02578680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02578680, "Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02578680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*